Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy

Luca Bello, Luisa Piva, Andrea Barp, Antonella Taglia, Esther Picillo, Gessica Vasco, Marika Pane, Stefano C. Previtali, Yvan Torrente, Elisabetta Gazzerro, Maria Chiara Motta, Gaetano S. Grieco, Giovanni Grieco, Sara Napolitano, Francesca Magri, Adele D'Amico, Guja Astrea, Sonia Messina, Maria Sframeli, Gian Luca VitaPatrizia Boffi, Tiziana Mongini, Alessandra Ferlini, Francesca Gualandi, Gianni Soraru, Mario Ermani, Giuseppe Vita, Roberta Battini, Enrico Bertini, Enrico Silvio Bertini, Giacomo P. Comi, Angela Berardinelli, Carlo Minetti, Claudio Bruno, Carmelina Bruno, Eugenio Maria Mercuri, Luisa Politano, Corrado Angelini, Carlo Angelini, Eric P. Hoffman, Elena Pegoraro

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

To test the effect of the single nucleotide polymorphism -66 T>G (rs28357094) in the osteopontin gene (SPP1) on functional measures over 12 months in Duchenne muscular dystrophy (DMD).
Original languageEnglish
Pages (from-to)159-162
Number of pages4
JournalNeurology
Volume79
DOIs
Publication statusPublished - 2012

Keywords

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Genetic Variation
  • Humans
  • Longitudinal Studies
  • Multicenter Studies as Topic
  • Muscular Dystrophy, Duchenne
  • Osteopontin
  • Polymorphism, Single Nucleotide
  • Retrospective Studies

Fingerprint

Dive into the research topics of 'Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this